Sequencing Therapies in LR-MDS
Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5.
- Please give an overview of 2L treatment strategies.
- If patients are refractory to the available 1L options, how would you choose a 2L treatment?
- Please give a brief overview of recent updates from IMerge (Santini et al, EHA 2024; Zeidan et al, JCO 2024).
- In your opinion, and considering NCCN Guidelines MDS-5, where do you see imetelstat in the treatment sequencing for LR-MDS?
- What can we learn from these studies and are there any remaining knowledge gaps to note?
Recent Videos
Related Content
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Article
Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
